Danaher Co. (NYSE:DHR) to Issue Quarterly Dividend of $0.18

Share on StockTwits

Danaher Co. (NYSE:DHR) declared a quarterly dividend on Tuesday, September 15th, RTT News reports. Investors of record on Monday, September 28th will be paid a dividend of 0.18 per share by the conglomerate on Friday, October 30th. This represents a $0.72 annualized dividend and a dividend yield of 0.35%.

Danaher has raised its dividend by 19.3% over the last three years and has raised its dividend annually for the last 3 consecutive years.

DHR stock traded up $0.76 during midday trading on Tuesday, hitting $208.69. The stock had a trading volume of 1,591,507 shares, compared to its average volume of 2,978,106. The firm has a market cap of $147.51 billion, a PE ratio of 44.69, a price-to-earnings-growth ratio of 3.22 and a beta of 0.91. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.20 and a quick ratio of 1.74. Danaher has a 12-month low of $119.60 and a 12-month high of $210.57. The company’s 50-day moving average price is $203.85 and its 200 day moving average price is $171.34.

Danaher (NYSE:DHR) last released its earnings results on Thursday, July 23rd. The conglomerate reported $1.44 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.09 by $0.35. The firm had revenue of $5.30 billion during the quarter, compared to analysts’ expectations of $5.01 billion. Danaher had a net margin of 17.73% and a return on equity of 11.88%. Danaher’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.09 EPS. As a group, sell-side analysts anticipate that Danaher will post 5.47 EPS for the current year.

Several analysts have recently issued reports on DHR shares. Robert W. Baird boosted their price objective on shares of Danaher from $163.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Needham & Company LLC boosted their price objective on shares of Danaher from $183.00 to $209.00 and gave the company a “buy” rating in a research note on Monday, July 27th. UBS Group boosted their price objective on shares of Danaher from $176.00 to $233.00 and gave the company a “buy” rating in a research note on Monday, July 27th. Royal Bank of Canada boosted their price objective on shares of Danaher from $205.00 to $218.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Finally, Jefferies Financial Group boosted their price objective on shares of Danaher from $190.00 to $230.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Danaher presently has a consensus rating of “Buy” and a consensus target price of $197.73.

In other Danaher news, Director Linda P. Hefner sold 2,754 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $197.00, for a total transaction of $542,538.00. Following the completion of the sale, the director now owns 32,749 shares in the company, valued at approximately $6,451,553. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Daniel L. Comas sold 100,032 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $194.56, for a total value of $19,462,225.92. Following the sale, the executive vice president now owns 134,933 shares of the company’s stock, valued at approximately $26,252,564.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 530,474 shares of company stock worth $104,501,669. Company insiders own 11.70% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.

Recommended Story: What is a Reverse Stock Split?

Dividend History for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.